Trial assessing DSP107, a first-in-class CD47x41BB targeting fusion protein, in blood cancers is being conducted at MD Anderson and funded by Cancer Focus Fund investment. Phase 1b clinical trial is an open label, dose escalation trial of DSP107 as monotherapy and in combination with azacitidine or with azacitidine plus venetoclax in patients with AML and MDS
